"I agree it's an agency problem. This why firms that are astute at making acquisitions properly align the incentives of managers and shareholders, and strive to make negotiating prowess a core competency (see [here](https://www.economist.com/news/finance-and-economics/21708671-two-economists-win-nobel-prize-their-work-theory-contracts-hard) and [here](https://www.economist.com/news/economics-brief/21725542-if-markets-are-so-good-directing-resources-why-do-companies-exist-first-our)). This is easier said than done - there are many more Valeant Pharmaceuticals type companies (making acquisitions for financial engineering and ""growth"") than Gilead Sciences type companies (making acquisitions based on a keen understanding of the market's demands)."